- Rating
- 3
- Confidence
- 3
- Informativeness
- 3
- Presentation
- 3
- Soundness
- 3(+1)
Read review
Paper summary
This paper proposes FREEDIA, a search-free pretraining framework for data-independent acquisition (DIA) spectra data. FreeDIA leverages DIA-Umpire to generate precursor–fragment attribution pseudo-labels from chromatographic co-elution patterns, enabling encoder pretraining without peptide sequence annotations. The pretrained encoder is subsequently fine-tuned for peptide sequencing, followed by a spectrum-evidence reranker to improve candidate selection. Across twodatasets, FREEDIA achieves strong performance under both unseen-peptide and sample-holdout evaluations.
Critical strengths
-
Search-free pretraining for DIA data. FreeDIA introduces a pretraining framework that does not require peptide sequence annotations, enabling the utilization of large-scale unidentified DIA data for representation learning.
-
Strong experimental performance. FreeDIA achieves strong results across two DIA datasets under both unseen-peptide and sample-holdout evaluations.
Critical weaknesses
-
Unclear peptide overlap between pretraining and downstream evaluation. Although the unseen-peptide split ensures no sequence overlap among the downstream training, validation, and test sets, the paper does not clearly report whether peptide sequences in the pretraining corpus overlap with those in the OC/UTI test sets. While pretraining does not use peptide sequence labels, potential exposure to test peptide spectra could still affect the interpretation of generalization to unseen peptides.
-
Although FreeDIA's main contribution is its pretraining framework, it additionally employs a reranker absent from DIANovo. Without the reranker, FreeDIA achieves lower peptide recall than DIANovo on both OC and UTI in the unseen-peptide setting.
Questions for authors
-
Could the authors report the peptide sequence overlap ratio between the pretraining corpus and the OC/UTI unseen-peptide test sets and evaluate performance after excluding overlapping test peptides?
-
Could the authors apply the same reranker to DIANovo or incorporate the proposed pretraining into DIANovo to better isolate the contribution of the pretraining framework?
Gentle Reminder
Dear Reviewer duZE,
Thank you again for your thoughtful review and constructive feedback. We have carefully addressed your concerns in our rebuttal, providing additional experimental results and clarifications.
As the discussion period is coming to a close, we would greatly appreciate it if you could review our responses. If you feel that your concerns have been sufficiently addressed, we would be grateful if you would consider updating your assessment.
Thank you for your time and consideration.